Neoadjuvant semaglutide before metabolic and bariatric surgery is not beneficial in terms of weight loss, according to study findings.

Updated results from the NIAGARA trial further support perioperative durvalumab and neoadjuvant chemotherapy as a potential new treatment for patients with muscle-invasive bladder cancer, according to ...

Two neoadjuvant immunotherapy combinations for head and neck cancer substantially increased the response rate versus a single ...

Use of nivolumab (Opdivo) before chemotherapy was not associated with improved pathologic complete response (pCR) rates among ...

Neoadjuvant nivolumab has demonstrated efficacy in patients with mismatch repair-deficient, surgically resectable endometrial cancer.

Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of ...

A recent study published in JAMA Oncology presents promising new data on a treatment regimen beneficial to patients with a ...

CEL-SCI (CVM) announced that a third-party study published on March 6 in JAMA Oncology provided data that support Multikine’s use as a ...

Administration of semaglutide before metabolic and bariatric surgery does not confer benefits for overall weight loss, ...

Gleevec response in GIST varies by mutational profile, with KIT-exon-11 mutation linked to better outcomes, emphasizing ...

No benefits seen in terms of weight loss, diabetes remission, surgery safety. (HealthDay News) — Neoadjuvant semaglutide before metabolic and bariatric surgery (MBS) is not beneficial in terms ...